Svetlana Faktorovich
Neurology · Boca Raton, FLNPI 1457790404
Payments from drug & device makers
Across 204 payments — averaging $239.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Johnson & Johnson$16K
- AbbVie$782
- EMD Serono, Inc.$255
- UCB, Inc.$224
- Akcea Therapeutics, Inc.$194
- plus $2K from 33 others
What the payments were for
- Consulting fees$8,45317%
- Speaking & faculty fees$31,10964%
- Travel & lodging$4,0598%
- Food & beverage$5,22411%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $30,021 |
| Johnson & Johnson | 27 | $15,770 |
| AbbVie(2 entities) | 37 | $782 |
| EMD Serono, Inc. | 15 | $255 |
| UCB, Inc. | 10 | $224 |
| Akcea Therapeutics, Inc. | 5 | $194 |
| Argenx US, Inc. | 3 | $173 |
| Amgen | 5 | $129 |
| Neurocrine Biosciences, Inc. | 5 | $121 |
| Lundbeck LLC | 4 | $116 |
| CSL Behring | 6 | $114 |
| Greenwich Biosciences, Inc. | 5 | $104 |
| Eisai Inc. | 5 | $96 |
| Neurelis, Inc. | 6 | $92 |
| Biogen | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Pfizer | 3 | $70 |
| Averitas Pharma Inc. | 2 | $58 |
| Grifols USA, LLC | 3 | $50 |
| TG Therapeutics, Inc. | 2 | $46 |
| Bristol Myers Squibb | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Ceribell, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Viz.ai, Inc. | 1 | $17 |
| Zimmer Biomet | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$23,065
- TEGSEDI$125
- VYVGART HYTRULO$125
How this compares
$48,949 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 12 | $688,917 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $330,262 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 27 | $204,382 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $201,302 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $168,951 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $145,632 |
| Nurtec OdtRimegepant Sulfate | 17 | $45,405 |
| Pyridostigmine Bromide | 32 | $3,850 |
| Gabapentin | 78 | $1,683 |
| Duloxetine Hcl | 75 | $1,550 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 18 | $1,105 |
| Levetiracetam | 12 | $741 |
| Memantine Hcl | 14 | $505 |
| Prednisone | 55 | $435 |
| Omeprazole | 18 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $25 | $688,91712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $28 | $330,26226 claims |
| PfizerOctagam, Nurtec Odt | $70 | $246,70739 claims |
| CSL BehringPrivigen | $114 | $168,95115 claims |
| Grifols USA, LLCGamunex-C | $50 | $145,63228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in Boca Raton
- Stuart IsaacsonBoca Raton$10.5M
- Brian SteingoBoca Raton$4.6M
- Marc FeinbergBoca Raton$3.2M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.